CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below.
All CIRM Grants
Search Filters »
| Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
| University of California, San Francisco |
Mort Cowan |
Clinical Trial Stage Projects |
Gene Transfer for Artemis-Deficient Severe Combined Immunodeficiency Using a Lentiviral Vector to Transduce Autologous CD34 Hematopoietic Stem Cells |
$12,000,000 |
| University of California, Los Angeles |
Dr. Steven M. Dubinett MD |
Clinical Trial Stage Projects |
A phase I trial of intratumoral administration of CCL21-gene modified dendritic cell (DC) combined with intravenous pembrolizumab for advanced NSCLC |
$10,955,315 |
| Medeor Acquisition Corp. |
Daniel Brennan |
Clinical Trial Stage Projects |
Cellular Immunotherapy for Induction of Immune Tolerance in HLA Matched Living Donor Kidney Transplant Recipients |
$11,217,155 |
| Poseida Therapeutics, Inc. |
Rajesh Belani MD |
Clinical Trial Stage Projects |
Clinical Study of T stem cell memory (Tscm)-based CAR-T cells in Patients with Multiple Myeloma |
$19,813,407 |
| Children’s Hospital of Los Angeles |
Michael A. Pulsipher |
Clinical Trial Stage Projects |
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES) |
$4,825,587 |
| Calibr |
Dr. Kristen A Johnson |
Clinical Trial Stage Projects |
Evaluation of the Safety and Tolerability of KA34 in a Phase 1, Double-Blind, Dose Escalation Trial in Patients with Knee Osteoarthritis |
$8,447,523 |
| Angiocrine Bioscience, Inc. |
Dr. Edward Kavalerchik |
Clinical Trial Stage Projects |
AB-110-001 Phase 1b Trial and Related Activities to Support Clinical Development of AB-110 |
$5,000,000 |
| SanBio, Inc. |
Dr. Bijan Nejadnik |
Clinical Trial Stage Projects |
A Double-Blind, Controlled Ph 2b Study of the Safety and Efficacy of Modified Stem Cells in Patients with Chronic Motor Deficit from Ischemic Stroke |
$18,970,000 |
| City of Hope, Beckman Research Institute |
Dr. Christine E. Brown |
Clinical Trial Stage Projects |
Phase I Study of Chimeric Antigen Receptor Engineered Central Memory T cells for the Treatment of Malignant Glioma |
$12,753,854 |
| University of California, San Diego |
Thomas J Kipps |
Clinical Trial Stage Projects |
A Phase 1b/2a Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in B-Cell Cancers |
$18,292,674 |
| Forty Seven Inc. |
Mark Chao |
Clinical Trial Stage Projects |
Phase 1b Trial of Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination with Azacitidine in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome |
$0 |
| BrainStorm Cell Therapeutics |
Dr. Ralph Kern |
Clinical Trial Stage Projects |
A Phase 3, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy & Safety of Repeated Administrations of NurOwn® in Patients with ALS |
$15,912,390 |
| Caladrius Biosciences |
Dr. William Sietsema |
Clinical Trial Stage Projects |
Phase 2 Safety and Efficacy Study of CLBS03 Autologous T-Regulatory Cells in Adolescents with Recent Onset Type 1 Diabetes Mellitus |
$8,175,946 |
| jCyte, Inc |
Henry John Klassen |
Clinical Trial Stage Projects |
Phase 2b Clinical Study of Safety and Efficacy of Intravitreal Injection of Retinal Progenitor Cells (jCell) for Treatment of Retinitis Pigmentosa |
$8,295,750 |
| Humacyte, Inc. |
Jeffrey Lawson |
Clinical Trial Stage Projects |
A Phase 3 Study Comparing the Utility of Human Acellular Vessels to Arteriovenous Fistula in Subjects with End-Stage Renal Disease (California Sites) |
$3,525,000 |
| ViaCyte, Inc. |
Manasi Jaiman |
Clinical Trial Stage Projects |
Clinical trial of directly vascularized islet cell replacement therapy for high-risk type 1 diabetes |
$13,607,002 |
| Forty Seven Inc. |
Mark Chao |
Clinical Trial Stage Projects |
A Phase 1b/2 Trial of the Anti-CD47 Antibody Hu5F9-G4 in Combination with Cetuximab in Patients with Solid Tumors and Advanced Colorectal Cancer |
$0 |
| Nohla Therapeutics Inc |
Dr. Colleen Delaney |
Clinical Trial Stage Projects |
A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Optimal Dose-Finding Study of DCC-UCB in Adults Receiving High Dose Chemotherapy for AML |
$4,310,000 |
| St. Jude Children’s Research Hospital |
Stephen Gottschalk |
Clinical Trial Stage Projects |
Lentiviral Gene Therapy for Infants with X-linked Severe Combined Immunodeficiency using Autologous Bone Marrow Stem Cells and Busulfan Conditioning |
$5,118,785 |
| Cedars-Sinai Medical Center |
Dr. Michael I Lewis |
Clinical Trial Stage Projects |
Pulmonary Arterial Hypertension Treated with Cardiosphere-Derived Allogeneic Stem Cells |
$7,354,772 |
| Stanford University |
Dr Robert Lowsky |
Clinical Trial Stage Projects |
Induction of Tolerance to Combined Kidney and Hematopoietic Progenitor Cell Transplants from HLA Haplotype Matched Living Donors |
$6,653,266 |
| University of California, Los Angeles |
Dr. Donald B. Kohn PhD |
Clinical Trial Stage Projects |
Efficacy and safety of cryopreserved autologous CD34+ HSC transduced with EFS lentiviral vector encoding for human ADA gene in ADA-SCID subjects |
$5,827,000 |
| Orchard Therapeutics plc |
Leslie Meltzer |
Clinical Trial Stage Projects |
Efficacy and safety of cryopreserved autologous CD34+ HSC transduced with EFS lentiviral vector encoding for human ADA gene in ADA-SCID subjects |
$2,638,745 |
| University of California, Los Angeles |
Dr. Donald B Kohn |
Clinical Trial Stage Projects |
Efficacy and safety of cryopreserved autologous CD34+ HSC transduced with EFS lentiviral vector encoding for human ADA gene in ADA-SCID subjects |
$10,156,925 |
| Cedars-Sinai Medical Center |
Professor Clive Niels Svendsen |
Clinical Trial Stage Projects |
Human Neural Progenitors Secreting Glial Cell Line-Derived Neurotrophic Factor (CNS10-NPC-GDNF) for the Treatment of Amyotrophic Lateral Sclerosis |
$6,154,067 |
| University of California, San Francisco |
Dr. Tippi C. MacKenzie |
Clinical Trial Stage Projects |
In Utero Hematopoietic Stem Cell Transplantation For The Treatment Of Fetuses With Alpha Thalassemia Major |
$9,350,000 |
| Humacyte, Inc. |
Jeffrey Lawson |
Clinical Trial Stage Projects |
A Human Acellular Vessel in Patients Needing Renal Replacement Therapy: A Comparison with ePTFE Grafts as Conduits for Hemodialysis (HUMANITY) |
$7,625,000 |
| Capricor, Inc |
Dr. Linda Marban |
Clinical Trial Stage Projects |
Allogeneic Cardiosphere-Derived Cells for Duchenne Muscular Dystrophy Cardiomyopathy |
$3,376,259 |
| University of California, Davis |
Dr Mehrdad Abedi |
Clinical Trial Stage Projects |
Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-selected CD34+ Cells in AIDS lymphoma patients |
$8,414,265 |
| ImmunoCellular Therapeutics |
Anthony J. Gringeri |
Clinical Trial Stage Projects |
A Phase III randomized double-blind, controlled study of ICT 107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy |
$5,391,016 |
| Caladrius Biosciences |
Robert Dillman |
Clinical Trial Stage Projects |
Tumor stem cell-targeted immunotherapy for metastatic melanoma –a randomized phase 3 clinical trial. |
$3,000,000 |
| University of California, Los Angeles |
Dr. Donald B. Kohn PhD |
Clinical Trial Stage Projects |
A Phase I/II, Non Randomized, Multicenter, Open-Label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease |
$7,083,364 |
| Rejuvenate Bio |
Deborah D. Ascheim |
Late Stage Preclinical Projects |
Novel Gene Therapy Targeting Multiple Pathological Drivers of Desmoplakin Associated Arrhythmogenic Cardiomyopathy |
$4,000,000 |
| University of California, San Diego |
Mark H Tuszynski |
Late Stage Preclinical Projects |
Human Embryonic Stem Cell-Derived Neural Stem Cells for Severe Spinal Cord Injury (SCI) |
$6,000,000 |
| University of California, Los Angeles |
Dr. Arjun Deb |
Late Stage Preclinical Projects |
Development of a therapeutic monoclonal antibody for the treatment of myocardial infarction and heart failure |
$5,999,998 |
| Children’s Hospital of Los Angeles |
Shahab Asgharzadeh |
Late Stage Preclinical Projects |
Chimeric TGFB Signaling Receptor (CTSR) Enabled Anti-B7H3 CAR T-cell Therapy in Children and AYA with Recurrent Solid Tumors |
$6,000,000 |
| University of California, San Francisco |
Thomas Martin |
Late Stage Preclinical Projects |
A 1XX-enhanced and fully non-viral BCMA CAR T cell therapy for Relapsed and Refractory Multiple Myeloma (UCCT-BCMA-1) |
$4,585,501 |
| Elpida Therapeutics |
Mr Terry Pirovolakis |
Late Stage Preclinical Projects |
Pre-Clinical To Clinical Gene Therapy Development For CMT4J |
$3,930,964 |
| AcuraStem Incorporated |
Mr. Samuel V. Alworth MS, MBA |
Late Stage Preclinical Projects |
Manufacturing of AS-202, an Antisense oligonucleotides for a Phase 1/2 Clinical Trial for Amyotrophic Lateral Sclerosis |
$0 |
| Cedars-Sinai Medical Center |
Dr. Eugenio Cingolani |
Late Stage Preclinical Projects |
Extracellular Vesicles for Ventricular Tachycardia |
$5,999,441 |
| City of Hope, Beckman Research Institute |
Prof. Karen S Aboody M.D. |
Late Stage Preclinical Projects |
Neural stem cell delivered CRAd-S-pk7 oncolytic viro-immunotherapy for ovarian cancer |
$5,314,547 |
| Tr1X Inc. |
Dr. Maria Grazia Roncarolo |
Late Stage Preclinical Projects |
TRX103 for prevention of GvHD in patients receiving HLA mismatched related or unrelated allogeneic HSCT for the treatment of hematologic malignancies. |
$4,000,000 |
| Mahzi Therapeutics |
Dr. Yael Weiss |
Late Stage Preclinical Projects |
Development of a Gene Therapy for the Treatment of WWOX related epileptic encephalopathy (WOREE) |
$4,000,000 |
| University of California, Davis |
Dr Mehrdad Abedi |
Late Stage Preclinical Projects |
Superior forward-oriented b-globin vector for treating Sickle Cell Disease |
$4,598,398 |
| Stanford University |
Dr. Matthew H Porteus |
Late Stage Preclinical Projects |
Autologous Gene Corrected Sinus Basal Cells to Treat Serious Cystic Fibrosis Sinus Disease |
$6,000,000 |
| University of California, Irvine |
Kyriacos A Athanasiou |
Late Stage Preclinical Projects |
Treatment of the TMJ disc complex |
$6,000,000 |
| Aspera Biomedicines, Inc. |
Catriona Jamieson |
Late Stage Preclinical Projects |
Cancer Stem Cell Interception with Rebecsinib: A First-in-Class ADAR1 Inhibitor |
$3,200,000 |
| University of California, Los Angeles |
Dr. Jerome A. Zack Ph.D. |
Late Stage Preclinical Projects |
Clinical Translation of Autologous Regenerative Pluripotent Stem Cell Therapy for Blindness |
$6,000,000 |
| Kenai Therapeutics |
Howard J Federoff |
Late Stage Preclinical Projects |
Allogeneic iPSC derived Dopaminergic Drug Product for Parkinson’s disease |
$4,000,000 |
| Rampart Bioscience |
Jeffrey Bartlett |
Late Stage Preclinical Projects |
Ex vivo Engineering of Autologous Hematopoietic Stem Cells for the Treatment of Hypophosphatasia |
$3,999,980 |
